Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3

Basit Öğe Kaydı
dc.contributor.authorBal, Tayibe
dc.contributor.authorÇabalak, Mehmet
dc.date.accessioned2024-09-19T16:26:48Z
dc.date.available2024-09-19T16:26:48Z
dc.date.issued2020
dc.departmentHatay Mustafa Kemal Ãœniversitesien_US
dc.description.abstractAim: Few studies have evaluated real-world clinical experience with sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV)genotypes 2 and 3 infections from Turkey. Thus, this study aimed to investigate the results of sofosbuvir plus ribavirin therapy ingenotype 2 and 3 cases followed in an infectious disease clinic at a university hospital in Hatay, southern Turkey.Material and Methods: In this single-centre, retrospective, observational study, 58 eligible patients treated with SOF/RBV (400 mgof SOF plus weight-based RBV) therapy between October 2016 and February 2019 were examined. Forty-three patients who hadcompleted the duration of treatment and had known virological response status were evaluated for treatment outcomes.Results: SOF/RBV achieves a sustained virological response (SVR) rate of 96.3% and 100% in the HCV genotype 2 and 3 groups,respectively, with treatment duration of 12-24 weeks. No patient experienced a virologic breakthrough while only one experiencedvirologic relapse after the completion of therapy. The incidence of adverse events was 25.5% (11/43) while the most common(11.6%) adverse event was ribavirin-related hemolytic anemia.Conclusion: The current study revealed that the SOF/RBV therapy achieved excellent response rates with a good safety profile innon-cirrhotic Turkish patients infected with HCV genotype 2 or 3.en_US
dc.identifier.doi10.5455/annalsmedres.2020.04.413
dc.identifier.endpage2071en_US
dc.identifier.issn2636-7688
dc.identifier.issue8en_US
dc.identifier.startpage2067en_US
dc.identifier.trdizinid383355en_US
dc.identifier.urihttps://doi.org/10.5455/annalsmedres.2020.04.413
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/383355
dc.identifier.urihttps://hdl.handle.net/20.500.12483/16358
dc.identifier.volume27en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofAnnals of Medical Researchen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleSofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
Ä°sim:
16358.pdf
Boyut:
138.48 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Ä°ndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu